AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-22	€0.5580	-2.11%	331,208
26-07-21	€0.5700	+1.06%	296,267
26-07-20	€0.5640	-7.84%	393,608
26-07-17	€0.6120	-0.97%	255,078
26-07-16	€0.6180	-4.19%	213,031

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-22 am EDT			5-day change	1st Jan Change
0.5580 ^EUR	-2.11%		-13.49%	-63.67%

Jul. 13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
Jul. 10	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	EV / Sales 2026 *	37.2x	EV / Sales 2027 *	34.3x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

Jul. 13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
Jul. 10	AB Science streamlines its portfolio and refocuses on two molecules
Jul. 10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
Jul. 08	Stéphane Ledermann takes the helm at AB Science as CEO
Jul. 06	AB Science S.A. Announces Board Changes	CI
Jul. 06	AB Science S.A. Announces CEO Changes	CI
Jul. 02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
Jul. 01	AB Science, successful private placement
Jun. 30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
Jun. 29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
Jun. 29	AB Science completes Step 3 of a Phase 1 study
Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib

Jul. 10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
Jul. 08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
Jul. 01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
Jun. 29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
Jun. 29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jul. 13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
Jul. 13	Wall Street ne chômera pas le 14 juillet
Jul. 10	AB Science rationalise son portefeuille et se recentre sur deux molécules
Jul. 10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
Jul. 08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	-2.11%
1 week	-13.49%
Current month	-36.95%
1 month	-35.86%
3 months	-52.23%
6 months	-61.14%
Current year	-63.67%

1 week	0.55	0.64
1 month	0.55	0.91
Current year	0.55	1.61
1 year	0.55	1.73
3 years	0.55	4.46
5 years	0.55	15.58
10 years	0.55	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/20/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
2/9/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
2/2/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.11%	-13.49%	-53.50%	-86.08%	52.03M
MERCK & CO., INC.	+0.96%	+3.12%	+56.19%	+15.47%	312B
MERCK KGAA	+1.97%	-2.28%	+25.65%	-11.82%	66.59B
HALOZYME THERAPEUTICS, INC.	-0.99%	+2.64%	+35.25%	+81.44%	9.32B
KYOWA KIRIN CO., LTD.	-1.07%	-1.76%	+3.03%	-4.80%	8.53B
SK BIOPHARMACEUTICALS CO., LTD.	-1.03%	-1.79%	-24.11%	-10.07%	4.1B
BETTA PHARMACEUTICALS CO., LTD.	+0.38%	-9.58%	-5.58%	+22.13%	3.76B
YUHAN CORPORATION	+0.86%	+1.01%	-43.84%	+10.01%	3.51B
SUPERNUS PHARMACEUTICALS, INC.	-1.94%	-1.66%	+43.68%	+53.35%	2.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.81%	-6.33%	+5.13%	-9.94%	2.19B
Average	-0.58%	-2.14%	+4.19%	+5.97%	41.27B
Weighted average by Cap.	+0.97%	+3.05%	+47.11%	+12.01%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.93M 132M 1.96M 13.27M 5.19M 64.67M 5.14M 5.03M 223M	1.3M 1.48M 1.21M 1.11M 2.09M 143M 2.12M 14.38M 5.63M 70.05M 5.57M 5.45M 242M
Net income	-	-
Net Debt	-	-